David Einhorn's Greenlight Capital took new positions in Fluor (FLR), with 760.6K shares, and Victoria's Secret (VSCO), with ...

A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending ...

Q2 2025 Earnings Call Transcript August 12, 2025 Theravance Biopharma, Inc. beats earnings expectations. Reported EPS is ...

YUPELRI® (revefenacin) net sales of $66.3 million, recognized by Viatris, increased 22% year-over-year1 Pivotal Phase 3 CYPRESS study enrollment on track to complete ...

Medication company Viatris (NASDAQ:VTRS) announced better-than-expected revenue in Q2 CY2025, but sales fell by 5.6% year on ...

Theravance Biopharma's Q2 2025 earnings show robust growth with YUPELRI sales up 22%, a $225M TRELEGY royalty sale, and progress in the pivotal CYPRESS trial.

The global pharmaceutical market reached a total value of US$1.38 trillion in 2024, according to Research and Markets, up significantly from the US$888 billion seen just over a decade earlier in 2010.

On Monday, the U.S. Food and Drug Administration (FDA) approved Amphastar Pharmaceuticals, Inc.’s (NASDAQ:AMPH) Abbreviated ...

A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed ...

Detailed price information for Lexicon Pharmaceutcl (LXRX-Q) from The Globe and Mail including charting and trades.

US generics major Viatris has won US Food and Drug Administration (FDA) approval for iron sucrose injection, USP, an ...